Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 10/20 | 0.48 |
| ▸ | AXL | P30530 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10453000 | 0.95 | FGFR2 (0.52) | PDGFRAFGFR2METAXLKDR | |
| SCHEMBL13955465 | 0.91 | FGFR2 (0.58) | PDGFRAFGFR2METAXLKDR | |
| SCHEMBL14821391 | 0.84 | AXL (0.57) | PDGFRAFGFR2METAXLKDR | |
| Bromide SCHEMBL15917915 | 0.83 | AXL (0.56) | PDGFRAFGFR2METAXLKDR | |
| SCHEMBL20216881 | 0.82 | FGFR2 (0.60) | PDGFRAFGFR2METAXLKDR | |
| SCHEMBL13936618 | 0.81 | PDGFRA (0.52) | PDGFRAFGFR2METAXLKDR | |
| SCHEMBL13955464 | 0.80 | MET (0.57) | METAXLKDR | |
| SCHEMBL13955466 | 0.80 | MET (0.57) | METAXLKDR | |
| SCHEMBL13787639 | 0.80 | SRC (0.61) | PDGFRAFGFR2METAXLKDR | |
| SCHEMBL12499486 | 0.80 | FGFR2 (0.56) | PDGFRAFGFR2METKDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | PDGFRA 229/4885FGFR2 1020/4885MET 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.